INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
8.04
-0.20 (-2.43%)
Apr 24, 2025, 4:00 PM EDT - Market closed
INmune Bio Revenue
In the year 2024, INmune Bio had annual revenue of $14.00K, down -90.97%.
Revenue (ttm)
$14.00K
Revenue Growth
-90.97%
P/S Ratio
13,168.55
Revenue / Employee
$636
Employees
22
Market Cap
184.36M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
Dec 31, 2020 | 11.00K | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
INMB News
- 10 days ago - INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness - GlobeNewsWire
- 4 weeks ago - INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha
- 5 weeks ago - INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results - Seeking Alpha
- 2 months ago - INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - GlobeNewsWire
- 2 months ago - INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewsWire
- 4 months ago - INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha